Media

Print

Information for journalists, editors and other members of the media

Press releases

 

LUNDBECK CANADA’S CONTRIBUTION TO UNIVERSITE LAVAL’S FACULTY OF PHARMACY AND CREATION OF A MASTER OF ADVANCED STUDIES IN PSYCHIATRY IN PARTNERSHIP WITH THE IUSMQ  - October 5, 2014

LUNDBECK ANNOUNCES HEALTH CANADA APPROVAL OF TRINTELLIX™ (vortioxetine hydrobromide) FRO THE TREATMENT OF ADULTS WITH MAJOR DEPRESSIVE DISORDER - October 28, 2014

NEW ONCE-MONTHLY TREATMENT FOR SCHIZOPHRENIA, ABILIFY MAINTENA (aripiprazole for prolonged release injectable suspension), NOW AVAILABLE IN CANADA - May 5, 2014

LUNDBECK CANADA LAUNCHES A NEW TREATMENT FOR A RARE FORM OF ACUTE LEUKEMIA- November 13, 2013

LUNDBECK CANADA OFFERS NEW TREATMENT OPTION FOR RELAPSED INDOLENT B-CELL NON-HODGKIN LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA
- September 13, 2012

LUNDBECK CANADA HAILS NEW NATIONAL STANDARD ON PSYCHOLOGICAL HEALTH AND SAFETY IN THE WORKPLACE
- January 16, 2013

 

Members of the media seeking further information may contact:
Daniel McCarthy
Senior Director, Public Affairs and Market Access
Tel 514-844-8515
DMY@Lundbeck.com

You are now leaving www.lundbeck.ca , Lundbeck Canada’s Web site. Links to site outside of Lundbeck Canada are provided as resources to visitors and may not represent Canada regulation or prescribing information. Lundbeck Canada accepts no responsibility in the content of linked sites.